A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer
NCT02032277
Completed
This is a 3 arm Phase 3 study to evaluate the safety and efficacy of the addition of veliparib plus carboplatin versus the addition of carboplatin to standard neoadjuvant chemotherapy versus standard neoadjuvant chemotherapy in subjects with early stage TNBC.
Gender:
FEMALE
Ages:
Between 18 years and 99 years
Trial Updated:
01/15/2021
Locations: Scottsdale Healthcare /ID# 120473, Scottsdale, Arizona +157 locations
Conditions: Triple Negative Breast Cancer
Register for Updates
ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung Cancer
NCT00662597
Terminated
The purpose of this study is to determine if adding ASA404 to standard chemotherapy makes the cancer treatment more effective in patients with advanced lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/16/2020
Locations: University of South Alabama/Mitchell Cancer Institute, Mobile, Alabama +248 locations
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
NCT02106546
Completed
The purpose of this study is to evaluate the safety and efficacy of the addition of veliparib plus carboplatin and paclitaxel versus the addition of placebo plus carboplatin and paclitaxel in adults with advanced or metastatic squamous non-small cell lung cancer (NSCLC).
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
11/13/2020
Locations: Northeast Arkansas Clinical Ch /ID# 128071, Jonesboro, Arkansas +224 locations
Conditions: Squamous Non-Small Cell Lung Cancer
Register for Updates
High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)
NCT01704716
Recruiting
This is a randomized study of the European SIOP Neuroblastoma Group (SIOPEN) in high-risk neuroblastoma (stages 2, 3, 4 and 4s MYCN-amplified neuroblastoma, stage 4 MYCN non amplified \> 12 months at diagnosis). The protocol consists of a rapid, dose intensive induction chemotherapy, peripheral blood stem cell harvest, attempted complete excision of the primary tumour, myeloablative therapy followed by peripheral blood stem cell rescue, radiotherapy to the site of the primary tumour and immunot... Read More
Gender:
ALL
Ages:
Between 1 month and 21 years
Trial Updated:
10/21/2020
Locations: Women and Children´s Hospital, Adelaide, Not set +125 locations
Conditions: Neuroblastoma
Register for Updates
Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian Cancer
NCT03704467
Completed
The study was to evaluate the efficacy and safety of avelumab in combination with M6620 + carboplatin in participants with PARPi-resistant, recurrent, platinum sensitive ovarian, primary peritoneal, or fallopian tube cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/21/2020
Locations: Marin Cancer Care, Inc., Greenbrae, California +12 locations
Conditions: Ovarian Cancer
Register for Updates
BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab
NCT00625898
Terminated
The trial will determine the value of adding bevacizumab to chemotherapy plus trastuzumab in patients with resected node-positive or high risk node-negative, HER2-positive breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
09/09/2020
Locations: University of Alabama at Birmingham, Birmingham, Alabama +648 locations
Conditions: Breast Cancer
Register for Updates
Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer
NCT02027428
Completed
Maintenance treatment of advanced stage squamous cell NSCLC. Phase III, randomized, open-label, multi-center study of nab-paclitaxel with best supportive care (BSC) or BSC alone as maintenance treatment after response or stable disease (SD) with nab-paclitaxel plus carboplatin as induction in subjects with stage IIIB/IV squamous cell NSCLC. Subjects who discontinued treatment from the maintenance part for any reason other than withdrawal of consent, lost to follow-up, or death, were entered in... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2020
Locations: Clearview Cancer Institute Oncology Specialties, P.C, Huntsville, Alabama +118 locations
Conditions: Squamous Cell Carcinoma, Non-Small-Cell Lung
Register for Updates
Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone
NCT01450761
Completed
The purpose of the study is to determine whether the addition of Ipilimumab to Etoposide and Platinum therapy will extend the lives of patients with Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) more than Etoposide and Platinum therapy alone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/06/2020
Locations: Genesis Cancer Center, Hot Springs, Arkansas +224 locations
Conditions: Small Cell Lung Carcinoma
Register for Updates
Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100)
NCT02718417
Terminated
This is a Phase 3, open-label, international, multi-center, efficacy, and safety study of avelumab in combination with and/or following platinum-based chemotherapy. Eligible patients must have previously untreated, histologically confirmed Stage III-IV epithelial ovarian (EOC), fallopian tube cancer (FTC), or primary peritoneal cancer (PPC) and be candidates for platinum-based chemotherapy. The primary purpose of the study is to demonstrate if avelumab given as single agent in the maintenance s... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/19/2020
Locations: Alabama Oncology, Alabaster, Alabama +319 locations
Conditions: Ovarian Cancer
Register for Updates
Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin
NCT01285609
Completed
The purpose of the study is to determine whether Ipilimumab plus Paclitaxel and Carboplatin will extend the lives of patients with squamous only non small cell lung cancer more than placebo plus Paclitaxel and Carboplatin.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/16/2020
Locations: Sharp Memorial Hospital, San Diego, California +289 locations
Conditions: Lung Cancer - Non Small Cell Squamous
Register for Updates
A Phase III Randomised Trial of Peri-Operative Chemotherapy Versus sUrveillance in Upper Tract Urothelial Cancer (POUT)
NCT01993979
Unknown
POUT is a multi-centred randomised controlled phase III trial. 345 patients who have undergone nephro-ureterectomy, are surgically staged pT2-pT4, N0-3 or are pT1 and node positive, and who are fit for adjuvant chemotherapy, will be randomised to four cycles of adjuvant platinum based chemotherapy (experimental group) or surveillance (control group). Participants will be followed up according to routine practice. Primary endpoint: Disease-free survival (DFS) Secondary endpoints: * Overall Sur... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2020
Locations: William Harvey Hospital, Ashford-Kent, England +60 locations
Conditions: Transitional Cell Carcinoma of Ureter
Register for Updates
Paclitaxel + Carboplatin With/ut BMS-275291 in Advanced or Metastatic Non-small Cell Lung Cancer
NCT00006229
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether paclitaxel and carboplatin are more effective with or without BMS-275291 for non-small cell lung cancer. PURPOSE: Randomized phase II/III trial to compare the effectiveness of paclitaxel and carboplatin with or without BMS-275291 in treating patients who have advanced or metastatic non-small cell lung cancer.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
04/02/2020
Locations: University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama +68 locations
Conditions: Lung Cancer
Register for Updates